Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.95 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.95 |
| ▸ | MLNR | O43193 | 1/20 | 0.95 |
| ▸ | ALB | P02768 | 1/20 | 0.95 |
| ▸ | CNR1 | P21554 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.95 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.95 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 0.88 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.88 |
| ▸ | AR | P10275 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.86 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL284866 | 1.00 | CYP3A4 (0.95) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL2328474 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL20833993 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL17119502 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL14342511 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL24415240 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL13930075 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL13900514 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL13105406 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL15472911 | 0.97 | CYP3A4 (1.00) | CYP3A4KCNH2ABCB1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431062-A | Process for preparing liquid fertilizer from erythromycin sulfate waste liquid | 黑龙江华洁安环保科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-112912386-A | Cell penetrating peptide based on influenza virus M2 protein | 中国医学科学院基础医学研究所 | 2021-06-04 | — | — | CN | claimed |
| US-10874771-B2 | Oriented P4HB implants containing antimicrobial agents | TEPHA, INC. (US) | 2020-12-29 | — | — | US | claimed |
| CN-101583339-B | Compositions comprising macromolecular assemblies of lipid and surfactant | MALVERN COSMECEUTICS LTD | 2013-10-23 | — | — | CN | claimed |
| EP-2428200-A2 | Novel compositions | Malvern Cosmeceutics Limited (GB) | 2012-03-14 | — | — | EP | claimed |
| US-20100062067-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2010-03-11 | — | — | US | claimed |
| CN-101583339-A | Compositions comprising macromolecular assemblies of lipid and surfactant | MALVERN COSMECEUTICS LTD (GB) | 2009-11-18 | — | — | CN | claimed |
| EP-2099410-A2 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | Malvern Cosmeceutics Limited (GB) | 2009-09-16 | — | — | EP | claimed |
| WO-2008065451-A2 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2008-06-05 | — | — | WO | claimed |
| CN-119841452-A | Composite technology and device for wastewater biological inhibition reduction and anaerobic membrane bioreactor | 中国科学院生态环境研究中心 | 2025-04-18 | — | — | CN | disclosed |
| CN-116213434-B | Treatment method of erythromycin thiocyanate fungus residues | 中广核达胜加速器技术有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-113861268-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119431062-A | Process for preparing liquid fertilizer from erythromycin sulfate waste liquid | 黑龙江华洁安环保科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20090155375-A1 | Compositions comprising a lipid and copolymer of styrene and maleic acid | MALVERN COSMECEUTICS LIMITED (GB) | 2009-06-18 | — | — | US | disclosed |
| WO-2008065451-A2 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | MALVERN COSMECEUTICS LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
| CN-101184473-A | Composition for use in the solubilisation of hydrophobic active agents | MALVERN COSMECEUTICS LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| EP-1890675-A1 | COMPOSITIONS COMPRISING A LIPID AND COPOLYMER OF STYRENE AND MALEIC ACID | Malvern Cosmeceutics Limited (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006129127-A1 | COMPOSITIONS COMPRISING A LIPID AND COPOLYMER OF STYRENE AND MALEIC ACID | MALVERN COSMECEUTICS LIMITED (GB) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155375-A1 | Compositions comprising a lipid and copolymer of styrene and maleic acid | COASY, ME1, HDLBP | CYP3A4 1287/4885KCNH2 4588/4885ABCB1 1923/4885 |
| US-20100062067-A1 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT | CLTB, APOB, ABCB4 | CYP3A4 4108/4885KCNH2 2186/4885ABCB1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.